News
GSK pursues $10.6bn takeover of cancer biotech Nuvalent
GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.
Sales & Marketing
Are pharma teams ready for the next customer engagement mode...
The infrastructure is largely in place.
News
SCOTUS backs generic firm Hikma in skinny label dispute
SCOTUS has delivered its ruling in a closely watched 'skinny label' lawsuit between Amarin and Hikma, which could have far-reaching implications.
News
Ahead of ASCO data drop, AZ gets key Imfinzi approval
AstraZeneca has claimed another key FDA approval for Imfinzi in bladder cancer, as an add-on to BCG therapy for early non-muscle invasive disease.
News
November date set for FDA decision on Sanofi's Gaucher drug
The FDA has started a priority review of Sanofi's brain-acting Gaucher disease therapy venglustat, with an action date of 25th November.
News
Press Releases
Views & Analysis
Editor's Picks
Editor's Picks
